The Ohio State University created the Center for Clinical and Translational Science (CCTS) to catalyze research teams and facilitate innovation through creation of an environment that fosters translation of knowledge to improve human health. The Center will accomplish four specific aims: 1) Build on the unique and diverse strengths of our institution to create an integrated academic home for innovative, team-oriented clinical and translational science; 2) Enhance and nurture the career development of highly trained investigators, with an emphasis on innovation and transdisciplinary science; 3) Integrate and enhance an administrative infrastructure to optimize the efficient conduct of the highest quality, generalizable clinical and translational science that is relevant to the community setting; 4) Develop, enhance and integrate a portfolio of outstanding shared resources in support of transformative clinical and translational research. The CCTS will continue to focus on integrating the traditional biomedical research process (basic scientific discovery with translation to the bedside to dissemination into the community for improved patient outcomes) with a public health model (surveillance to prevention to response). By incorporating this bi-directional model in the creation of a robust translational science infrastructure, the OSU CCTS will foster both the traditional discovery to best practice paradigm as well as taking advantage of the insight garnered from our foundation of excellence in clinical care to stimulate basic discovery and clinical research inquiry. The vision and specific aims will be achieved through an integrated model of governance and partnership, home, and leadership for clinical and translational research spanning NCH and OSU; focused pilot funding initiatives for new team development within an innovation ecosystem; unique educational and training architecture which integrates acquisition of core competencies in research methodology, interpretation of results, implementation of findings, design thinking, team leadership skills and business acumen with rigorous discipline-specific laboratory (bench, clinical or community) training; and a clinical and translational science infrastructure that is cohesive, innovative and adaptable and more effective than the services that currently exist in order to ensure provision of the full range of disease-agnostic scientific resources needed to traverse the continuum of research from T1-4.

Public Health Relevance

(See Instructions): The Center for Clinical and Translational Science will improve human health by bringing the benefits of science more quickly into patient care.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR001070-04S2
Application #
9326372
Study Section
Special Emphasis Panel (ZAI1-PTM-C (S1))
Program Officer
Wilson, Todd
Project Start
2013-09-26
Project End
2018-04-30
Budget Start
2017-01-01
Budget End
2017-04-30
Support Year
4
Fiscal Year
2017
Total Cost
$463,179
Indirect Cost
$95,159
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Hankey, William; Chen, Zhong; Bergman, Maxwell J et al. (2018) Chromatin-associated APC regulates gene expression in collaboration with canonical WNT signaling and AP-1. Oncotarget 9:31214-31230
Gross, Amy C; Cam, Hakan; Phelps, Doris A et al. (2018) IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight 3:
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
McDonald, Craig M; Wong, Brenda; Flanigan, Kevin M et al. (2018) Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy. Ann Clin Transl Neurol 5:913-926
Tan, Alai; Sullenbarger, Brent; Prakash, Ruchika et al. (2018) Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: A randomized, controlled study. Prostaglandins Leukot Essent Fatty Acids 132:23-29
Olson, KayLoni L; Thaxton, Tyler T; Emery, Charles F (2018) Targeting body dissatisfaction among women with overweight or obesity: A proof-of-concept pilot study. Int J Eat Disord 51:973-977
Felgenhauer, Joshua; Tomino, Laura; Selich-Anderson, Julia et al. (2018) Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. Neoplasia 20:965-974
Sinha, Mithun; Sen, Chandan K; Singh, Kanhaiya et al. (2018) Direct conversion of injury-site myeloid cells to fibroblast-like cells of granulation tissue. Nat Commun 9:936
Kiecolt-Glaser, Janice K; Wilson, Stephanie J; Bailey, Michael L et al. (2018) Marital distress, depression, and a leaky gut: Translocation of bacterial endotoxin as a pathway to inflammation. Psychoneuroendocrinology 98:52-60

Showing the most recent 10 out of 473 publications